{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:22:05Z","timestamp":1790511725985,"version":"4.1.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MH CZ - DRO (FNOs\/2018)"],"award-info":[{"award-number":["MH CZ - DRO (FNOs\/2018)"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["IRP03_2018-2020"],"award-info":[{"award-number":["IRP03_2018-2020"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02431","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T05:35:02Z","timestamp":1542346502000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":100,"title":["Update on PD-1\/PD-L1 Inhibitors in Multiple Myeloma"],"prefix":"10.3389","volume":"9","author":[{"given":"Tomas","family":"Jelinek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14735\/amko20172S35","article-title":"Epidemiology of multiple myeloma in the Czech Republic","volume":"30","author":"Maluskova","year":"2017","journal-title":"Klin Onkol Cas Ceske Slov Onkol Spolecnosti"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2017","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.blre.2015.08.004","article-title":"Monoclonal antibodies - A new era in the treatment of multiple myeloma","volume":"30","author":"Jelinek","year":"2016","journal-title":"Blood Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.14735\/amko201713","article-title":"Daratumumab-hope for myeloma patients, a challenge for clinical laboratories","volume":"30","author":"Jel\u00ednek","year":"2017","journal-title":"Klin Onkol Cas Ceske Slov Onkol Spolecnosti"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/imm.12788","article-title":"PD-1\/PD-L1 inhibitors in haematological malignancies: update 2017","volume":"152","author":"Jelinek","year":"2017","journal-title":"Immunology"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"B20","unstructured":"Safety and efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with cyclophosphamide conditioning for refractory Multiple Myeloma (MM)505 CohenAD GarfallAL StadtmauerEA LaceySF LancasterE VoglDT Blood1302017"},{"key":"B21","unstructured":"Durable clinical responses in heavily pretreated patients with relapsed\/refractory multiple myeloma: updated results from a multicenter study of bb2121 Anti-Bcma CAR T cell therapy740 BerdejaJG LinY RajeN MunshiN SiegelD LiedtkeM Blood1302017"},{"key":"B22","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune checkpoint blockade in hematologic malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1002\/eji.200324270","article-title":"Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis","volume":"33","author":"Rodig","year":"2003","journal-title":"Eur J Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide Enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/leu.2017.272","article-title":"Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy","volume":"32","author":"Kelly","year":"2018","journal-title":"Leukemia"},{"key":"B42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0139867","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 Expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PLoS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"B45","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.critrevonc.2016.01.004","article-title":"Immunomodulatory drugs in AL amyloidosis","volume":"99","author":"Jelinek","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.leukres.2012.05.010","article-title":"Mechanism of immunomodulatory drugs in multiple myeloma","volume":"36","author":"Sedlarikova","year":"2012","journal-title":"Leuk Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"24031","DOI":"10.18632\/oncotarget.15234","article-title":"Activation of NK cells and disruption of PD-L1\/PD-1 axis: two different ways for lenalidomide to block myeloma progression","volume":"8","author":"Giuliani","year":"2017","journal-title":"Oncotarget"},{"key":"B49","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1182\/bloodadvances.2017004382","article-title":"PD-1 blockade enhances elotuzumab efficacy in mouse tumor models","volume":"1","author":"Bezman","year":"2017","journal-title":"Blood Adv."},{"key":"B50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.7_suppl.79","article-title":"CD38 as a Novel Immune Checkpoint and a Mechanism of Resistance to the Blockade of the PD-1\/PD-L1 Axis","author":"Chen","year":""},{"key":"B51","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1158\/1538-7445.AM2018-1727","article-title":"Abstract 1727: antitumor activity associated with dual targeting of CD38 and programmed death-1 (PD-1) pathways in preclinical models","volume":"78","author":"Bezman","year":"2018","journal-title":"Cancer Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e1254856","DOI":"10.1080\/2162402X.2016.1254856","article-title":"PD-1\/PD-L1 inhibitors in multiple myeloma: the present and the future","volume":"5","author":"Jelinek","year":"2016","journal-title":"OncoImmunology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ccell.2015.03.015","article-title":"Radiotherapy complements immune checkpoint blockade","volume":"27","author":"Ngiow","year":"2015","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.molmed.2015.05.007","article-title":"Radiotherapy and immune checkpoint blockade: potential interactions and future directions","volume":"21","author":"Binder","year":"2015","journal-title":"Trends Mol Med."},{"key":"B57","unstructured":"Programmed death receptor-1\/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma56208 KearlTJ JingW GershanJA JohnsonBD 10.4049\/jimmunol.120200523616570J Immunol Baltim Md 19501902013"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B61","unstructured":"PEMBROLIZUMAB MONOTHERAPY FOR RELAPSED\/REFRACTORY MULTIPLE MYELOMA RibragV AviganDE MartinelliG GreenDJ TrishaW-D PosadaJG SiegelD Poster Presentation, Abstract: P344.2018"},{"key":"B62","unstructured":"PEMBROLIZUMAB PLUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR Rodriguez-OteroP MateosM-V OrlowskiR SiegelD ReeceD MoreauP MiguelJS Rodriguez-OteroP Oral Presentation, Abstract: S7832018"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"key":"B64","unstructured":"A phase II trial of the anti -PD-1 monoclonal antibody pembrolizumab (MK-3475) + lenalidomide + dexamethasone as post autologous stem cell transplant consolidation in patients with high-risk multiple myeloma1831 BiranN AndrewsT FeinmanR VesoleDH RichterJR ZenreichJ AnandP McBrideL IvanovskiK KorngoldR Blood1302017"},{"key":"B65","unstructured":"Phase 2 Study of pembrolizumab during lymphodepleted state after autologous hematopoietic cell transplantation in multiple myeloma patients339 PawarodeA D'SouzaA PasquiniMC JohnsonB BraunT DhakalB Blood1302017"},{"key":"B66","unstructured":"Immune predictors of response to pembrolizumab monotherapy as consolidation in multiple myeloma patients: results of the GEM-Pembresid clinical trial1874 OcioEM PuigN CorcheteL P\u00e9rezJJ D\u00e1vilaJ Pa\u00ednoT Blood1302017"},{"key":"B67","unstructured":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039)183 AnsellS GutierrezME ShippMA GladstoneD MoskowitzA BorelloI Popa-MckiverM FarsaciB ZhuL LesokhinAM Blood1282016"},{"key":"B68","unstructured":"Preliminary safety and efficacy data for combined checkpoint inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies - Cpit-001 trial340 SkarbnikAP DonatoML RowleySD GoyA VesoleDH MunshiPN Blood1302017"},{"key":"B69","article-title":"Paper: First Interim Results of a Phase I\/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed\/Refractory Multiple Myeloma","author":"Efebera","year":""},{"key":"B70","article-title":"Paper: Blockade of PD-1 in Combination with Dendritic Cell\/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease","author":"Rosenblatt","year":""},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8021","article-title":"A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed\/refractory multiple myeloma (RRMM): KEYNOTE-183","volume-title":"Poster session, Abstract 8021","author":"Mateos","year":"2018"},{"key":"B72","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8010","article-title":"A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185","volume-title":"Poster Discussion Session, Abstract 8010","author":"Usmani","year":"2018"},{"key":"B73","unstructured":"Pilot study of pembrolizumab for immunoprevention in smoldering multiple myeloma3089 ManasanchEE MathurR LeeHC WeberDM PatelKK ThomasSK Blood1302017"},{"key":"B74","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"B79","volume-title":"FDA Analysis of Pembrolizumab Trials in Multiple Myeloma: Immune Related Adverse Events (irAEs) and Response.","author":"Krauss","year":""},{"key":"B80","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.3324\/haematol.2017.185777","article-title":"Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity","volume":"103","author":"Martinez-Calle","year":"2018","journal-title":"Haematologica"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"B82","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-018-0589-1","article-title":"Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1\/PD-L1 pathway","volume":"11","author":"Tremblay-LeMay","year":"2018","journal-title":"J Hematol OncolJ Hematol Oncol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02431\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T10:02:17Z","timestamp":1605434537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02431\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":82,"alternative-id":["10.3389\/fimmu.2018.02431"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02431","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"article-number":"2431"}}